Oculus Innovative Sciences Announces Initial Chinese Commercialization Plan For Launch Of Microcyn(R) Technology Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn� Technology platform that is intended to treat infections in chronic and acute wounds, announced that the Oculus development team completed meetings this past week in Beijing, China with Chinese partners at China Bao Tai and Sinopharm regarding commercialization plans for the product launch of Microcyn Technology in China.
Source: www.medicalnewstoday.comBirkman Method Helps Pharma Reps Find New Jobs Eight of the world's largest drug makers recently announced the loss of 42,000 jobs, including such household names as Pfizer and Wyeth. The job losses fell disproportionately on their U.S. sales forces. Clearly, the days of growth for drug sales reps are seemingly over.
Source: www.medicalnewstoday.comOn The Eve Of ''ILSI-Biomed Israel 2008'' Week: Chief Scientist Approves More Than 305 Million NIS For The Life Science Industry Figures reported by the Chief Scientist office towards the "ILSI-Biomed Israel 2008" Week, which will be held in Tel Aviv from May 27-29, show that in the six months from November 2007 to April 2008, the Chief Scientist office earmarked 305.4 million NIS in budgets for the life science industry. When broken down into industry segments, bio-pharma received 77 million NIS, biotechnology 153.9 million NIS, and medical devices 74.5 NIS.
Source: www.medicalnewstoday.comLabels: No Prescription, Online Pharmacy
# posted by Network @ 5:00 AM
